Gene info: ID 5864

Gene: RAB3A

GENE ID: 5864

Synonyms: -

Description: RAB3A, member RAS oncogene family

Gene type: protein-coding

Location: 19p13.11

dbXrefs: Ensembl:ENSG00000105649 MIM:179490 Vega:OTTHUMG00000137378 UniprotKB:P20336

RefSeq: NC_000019.10

Retrived from: PubMed

SNPs: 0 ANCO-SNPs

Phenotype: CD

# Publications: 1

Sherlock p-value : NA (AD) NA (ND) (Frontal_Cortex)

Pascal p-value : 7.254e-1 (AD) 1.111e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
SULT4A1	0.984
SYP	0.982
SCAMP5	0.981
SV2A	0.981
ATP1A3	0.979
STXBP1	0.978
STX1B	0.975
SYNGR3	0.975
DNM1	0.974
SYNGR1	0.973

Top 10 negatively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
OR4F5	-0.58
TFPI2	-0.549
OR4F29	-0.537
REST	-0.52
KCNJ15	-0.511
WWTR1	-0.509
IL18RAP	-0.501
RAI14	-0.5
CXCR2	-0.497
CNN2	-0.489

There is no DrugBank record for this gene !

ID	Drug Name	Action	PubMed
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB3A mRNA"	27188386
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB3A mRNA"	27188386
D000082	Acetaminophen	Acetaminophen results in decreased expression of RAB3A mRNA	22230336
D000082	Acetaminophen	Acetaminophen results in increased expression of RAB3A mRNA	21420995
C020763	alpha-latrotoxin	[alpha-latrotoxin promotes the reaction [RAB3A protein results in increased cleavage of Guanosine Triphosphate]] promotes the reaction [Guanosine Diphosphate binds to RAB3A protein]	7929154
D000643	Ammonium Chloride	Ammonium Chloride affects the expression of RAB3A mRNA	16483693
D000068180	Aripiprazole	Aripiprazole results in increased expression of RAB3A mRNA	17868501
D001280	Atrazine	Atrazine results in increased expression of RAB3A mRNA	22378314
C551172	bis-N,N-dimethylamino-2-(N-methylpyrrolyl)methyl cyclopentadienyl titanium (IV)	"bis-N,N-dimethylamino-2-(N-methylpyrrolyl)methyl cyclopentadienyl titanium (IV) results in decreased expression of RAB3A mRNA"	20162321
C006780	bisphenol A	bisphenol A results in decreased expression of RAB3A mRNA	25181051
C038599	black widow spider venom	[black widow spider venom promotes the reaction [RAB3A protein results in increased cleavage of Guanosine Triphosphate]] promotes the reaction [Guanosine Diphosphate binds to RAB3A protein]	7929154
D003042	Cocaine	Cocaine results in increased expression of RAB3A mRNA	16076954
D019327	Copper Sulfate	Copper Sulfate results in increased expression of RAB3A mRNA	19549813
D002945	Cisplatin	[Cisplatin co-treated with jinfukang] results in increased expression of RAB3A mRNA	27392435
C000944	dicrotophos	dicrotophos results in increased expression of RAB3A mRNA	28302478
C118739	entinostat	entinostat results in increased expression of RAB3A mRNA	26272509
C118739	entinostat	"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB3A mRNA"	27188386
D005038	Ethylnitrosourea	Ethylnitrosourea results in increased mutagenesis of RAB3A gene	16724327
C069837	fullerene C60	fullerene C60 results in increased expression of RAB3A mRNA	19167457
C039281	furan	furan results in decreased expression of RAB3A mRNA	24183702
D006153	Guanosine Diphosphate	[alpha-latrotoxin promotes the reaction [RAB3A protein results in increased cleavage of Guanosine Triphosphate]] promotes the reaction [Guanosine Diphosphate binds to RAB3A protein]	7929154
D006153	Guanosine Diphosphate	[black widow spider venom promotes the reaction [RAB3A protein results in increased cleavage of Guanosine Triphosphate]] promotes the reaction [Guanosine Diphosphate binds to RAB3A protein]	7929154
D006153	Guanosine Diphosphate	Guanosine Diphosphate binds to RAB3A protein	7929154
D006160	Guanosine Triphosphate	[alpha-latrotoxin promotes the reaction [RAB3A protein results in increased cleavage of Guanosine Triphosphate]] promotes the reaction [Guanosine Diphosphate binds to RAB3A protein]	7929154
D006160	Guanosine Triphosphate	[black widow spider venom promotes the reaction [RAB3A protein results in increased cleavage of Guanosine Triphosphate]] promotes the reaction [Guanosine Diphosphate binds to RAB3A protein]	7929154
D006160	Guanosine Triphosphate	Guanosine Triphosphate binds to RAB3A protein	7929154
D006160	Guanosine Triphosphate	RAB3A protein results in increased cleavage of Guanosine Triphosphate	7929154
D006418	Heme	Heme metabolite results in decreased expression of RAB3A mRNA	19191707
D006830	Hydralazine	[Hydralazine co-treated with Valproic Acid] results in increased expression of RAB3A mRNA	17183730
C544151	jinfukang	[Cisplatin co-treated with jinfukang] results in increased expression of RAB3A mRNA	27392435
C561695	(+)-JQ1 compound	(+)-JQ1 compound results in increased expression of RAB3A mRNA	24796395
D008095	Lithocholic Acid	Lithocholic Acid binds to RAB3A protein	18641422
C004925	methylmercuric chloride	methylmercuric chloride results in decreased expression of RAB3A protein	25809596
D015632	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine promotes the reaction [SNCA protein mutant form binds to RAB3A protein]"	15099020
D009020	Morphine	Morphine affects the expression of RAB3A protein	16522322
D037742	Nanotubes, Carbon	"Nanotubes, Carbon analog results in decreased expression of RAB3A mRNA"	25554681
D037742	Nanotubes, Carbon	"Nanotubes, Carbon results in decreased expression of RAB3A mRNA"	25554681
C028007	nickel monoxide	nickel monoxide results in increased expression of RAB3A mRNA	19167457
D010126	Ozone	Ozone results in decreased expression of RAB3A mRNA	16330353
C006253	pirinixic acid	pirinixic acid results in decreased expression of RAB3A mRNA	23811191
C005556	propionaldehyde	propionaldehyde results in increased expression of RAB3A mRNA	26079696
D012402	Rotenone	Rotenone promotes the reaction [SNCA protein mutant form binds to RAB3A protein]	15099020
C017947	sodium arsenite	sodium arsenite results in increased expression of RAB3A mRNA	12016162
D012969	Sodium Fluoride	Sodium Fluoride results in increased expression of RAB3A protein	27548804
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin affects the expression of RAB3A mRNA	21570461
D013749	Tetrachlorodibenzodioxin	[Tetrachlorodibenzodioxin co-treated with TIPARP gene mutant form] results in decreased expression of RAB3A mRNA	25975270
D024505	Tocopherols	Tocopherols results in increased expression of RAB3A mRNA	17654050
C012589	trichostatin A	trichostatin A results in increased expression of RAB3A mRNA	23558232
D014635	Valproic Acid	[Hydralazine co-treated with Valproic Acid] results in increased expression of RAB3A mRNA	17183730
D014635	Valproic Acid	Valproic Acid affects the expression of RAB3A mRNA	25979313
D014635	Valproic Acid	Valproic Acid results in increased expression of RAB3A mRNA	28001369
C025643	vinclozolin	vinclozolin results in decreased expression of RAB3A mRNA	23034163
C025643	vinclozolin	vinclozolin results in increased expression of RAB3A mRNA	23869203
D015032	Zinc	Zinc deficiency results in increased expression of RAB3A mRNA	18356318
D015032	Zinc	[MT3 protein binds to RAB3A protein] which results in decreased susceptibility to Zinc	15039103

GO/Pathway

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0001671	ATPase activator activity	-	IEA	-
GO:0003924	GTPase activity	-	IBA	21873635
GO:0003924	GTPase activity	-	IDA	24891604
GO:0003924	GTPase activity	-	IMP	10859313
GO:0005515	protein binding	-	IPI	10859313 24891604 25416956
GO:0005525	GTP binding	-	IEA	-
GO:0008022	protein C-terminus binding	-	IEA	-
GO:0030742	GTP-dependent protein binding	-	IEA	-
GO:0031489	myosin V binding	-	IPI	24006491
GO:0051021	GDP-dissociation inhibitor binding	-	IEA	-
GO:0051117	ATPase binding	-	IEA	-

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0003016	respiratory system process	-	IEA	-
GO:0006886	intracellular protein transport	-	IBA	21873635
GO:0006904	vesicle docking involved in exocytosis	-	IBA	21873635
GO:0007005	mitochondrion organization	-	IEA	-
GO:0007274	neuromuscular synaptic transmission	-	IEA	-
GO:0007409	axonogenesis	-	IBA	21873635
GO:0007409	axonogenesis	-	IEA	-
GO:0009306	protein secretion	-	IBA	21873635
GO:0009791	post-embryonic development	-	IEA	-
GO:0014047	glutamate secretion	-	TAS	-
GO:0015031	protein transport	-	IEA	-
GO:0016079	synaptic vesicle exocytosis	-	ISS	-
GO:0016188	synaptic vesicle maturation	-	IEA	-
GO:0017157	regulation of exocytosis	-	IBA	21873635
GO:0030324	lung development	-	IEA	-
GO:0031630	regulation of synaptic vesicle fusion to presynaptic active zone membrane	-	IBA	21873635
GO:0031630	regulation of synaptic vesicle fusion to presynaptic active zone membrane	-	ISS	-
GO:0032482	Rab protein signal transduction	-	IBA	21873635
GO:0032781	positive regulation of ATPase activity	-	IEA	-
GO:0036465	synaptic vesicle recycling	-	ISS	-
GO:0043312	neutrophil degranulation	-	TAS	-
GO:0043687	post-translational protein modification	-	TAS	-
GO:0045054	constitutive secretory pathway	-	TAS	15217342
GO:0045921	positive regulation of exocytosis	-	TAS	15217342
GO:0048172	regulation of short-term neuronal synaptic plasticity	-	ISS	-
GO:0048790	maintenance of presynaptic active zone structure	-	IBA	21873635
GO:0048790	maintenance of presynaptic active zone structure	-	IEA	-
GO:0050808	synapse organization	-	IBA	21873635
GO:0050975	sensory perception of touch	-	IEA	-
GO:0051602	response to electrical stimulus	-	IEA	-
GO:0061670	evoked neurotransmitter secretion	-	IEA	-
GO:0072659	protein localization to plasma membrane	-	IBA	21873635
GO:1903307	positive regulation of regulated secretory pathway	-	IMP	22899725

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0001669	acrosomal vesicle	-	IEA	-
GO:0005768	endosome	-	IBA	21873635
GO:0005768	endosome	-	IEA	-
GO:0005829	cytosol	-	TAS	-
GO:0005886	plasma membrane	-	IBA	21873635
GO:0005886	plasma membrane	-	TAS	-
GO:0008021	synaptic vesicle	-	IBA	21873635
GO:0008021	synaptic vesicle	-	ISS	-
GO:0012505	endomembrane system	-	IBA	21873635
GO:0030424	axon	-	IBA	21873635
GO:0030424	axon	-	ISS	-
GO:0030667	secretory granule membrane	-	IBA	21873635
GO:0030667	secretory granule membrane	-	TAS	-
GO:0031410	cytoplasmic vesicle	-	IBA	21873635
GO:0031982	vesicle	-	IBA	21873635
GO:0032991	protein-containing complex	-	IEA	-
GO:0043195	terminal bouton	-	ISS	-
GO:0060201	clathrin-sculpted acetylcholine transport vesicle membrane	-	TAS	-
GO:0060203	clathrin-sculpted glutamate transport vesicle membrane	-	TAS	-
GO:0061202	clathrin-sculpted gamma-aminobutyric acid transport vesicle membrane	-	TAS	-
GO:0070083	clathrin-sculpted monoamine transport vesicle membrane	-	TAS	-
GO:0098993	anchored component of synaptic vesicle membrane	-	IBA	21873635
GO:0098993	anchored component of synaptic vesicle membrane	-	IEA	-
GO:1903561	extracellular vesicle	-	HDA	24769233

KEGG ID	KEGG Term

Reactome ID	Reactome Term	Evidence
R-HSA-112310	Neurotransmitter release cycle	TAS
R-HSA-112315	Transmission across Chemical Synapses	TAS
R-HSA-112316	Neuronal System	TAS
R-HSA-168249	Innate Immune System	TAS
R-HSA-168256	Immune System	TAS
R-HSA-181429	Serotonin Neurotransmitter Release Cycle	TAS
R-HSA-181430	Norepinephrine Neurotransmitter Release Cycle	TAS
R-HSA-199991	Membrane Trafficking	TAS
R-HSA-210500	Glutamate Neurotransmitter Release Cycle	TAS
R-HSA-212676	Dopamine Neurotransmitter Release Cycle	TAS
R-HSA-264642	Acetylcholine Neurotransmitter Release Cycle	TAS
R-HSA-392499	Metabolism of proteins	TAS
R-HSA-5653656	Vesicle-mediated transport	TAS
R-HSA-597592	Post-translational protein modification	TAS
R-HSA-6798695	Neutrophil degranulation	TAS
R-HSA-8873719	RAB geranylgeranylation	TAS
R-HSA-8876198	RAB GEFs exchange GTP for GDP on RABs	TAS
R-HSA-888590	GABA synthesis, release, reuptake and degradation	TAS
R-HSA-9007101	Rab regulation of trafficking	TAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID	Title (Year)	Author	Journal
21426264	Candidate pathway association study in cocaine dependence: the control of neurotransmitter release. (2012 Feb)	Fernandez-Castillo N	World J Biol Psychiatry